Changes in cerebral glucose metabolism in patients with mild-to-moderate Alzheimer's disease: A pilot study with the Chinese herbal medicine fuzhisan

Neuroscience Letters

Volumn 501, Issue 1, 2011, Pages 35-40

  Bi, Min ^a   Tong, Suijun ^b   Zhang, Zhaoxu ^a   Ma, Qilin ^b   Zhang, Shiyang ^b   Luo, Zuomin ^b   Zhang, Yidan ^b   Li, Xuling ^a   Wang, Desheng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Fuzhisan; Positron emission tomography; Regional cerebral metabolic rate of glucose consumption

Indexed keywords

FUZHISAN; HERBACEOUS AGENT; PLACEBO; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ALZHEIMER'S DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; BEHAVIOR; BRAIN FUNCTION; BRAIN REGION; CHINESE MEDICINE; CLINICAL ARTICLE; COGNITION; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MALE; NAUSEA; NEUROLOGIC EXAMINATION; NEUROPSYCHIATRIC INDEX; PARIETAL CORTEX; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TEMPORAL CORTEX; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN MAPPING; CEREBRAL CORTEX; COGNITION; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; GLUCOSE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS;

EID: 79960976449     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.06.036     Document Type: Article

References (24)

1. Bancher C., Brunner C., Lassmann H., Budka H., Jellinger K., Wiche G., Seitelberger F., Grundke-Iqbal I., Iqbal K., Wisniewski H.M. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 1989, 477:90-99.
2. Baozhi G., Baofeng Y., Desheng W., Zhijie Y., Duo M. Effects of Chinese compound fuzhisan on regional perfuse index in patients with Alzheimer disease. Chin. J. Neuroimmunol. Neurol. 2008, 15:420-422.
3. Blin J., Ivanoiu A., De Volder A., Michel C., Bol A., Verellen C., Seron X., Duprez T., Laterre E.C. Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease. Psychopharmacology (Berl) 1998, 136:256-263.
4. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
5. Desheng W., Xiaoyun X., Shirong W. The efficacy of FZS, nimodipine, GM1 in Alzheimer's disease. Inform. Tradit. Chin. Med. 1998, 15:49-51.
6. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., Schwaiger M., Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:1104-1113.
7. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
8. Herholz K., Salmon E., Perani D., Baron J.C., Holthoff V., Frolich L., Schonknecht P., Ito K., Mielke R., Kalbe E., Zundorf G., Delbeuck X., Pelati O., Anchisi D., Fazio F., Kerrouche N., Desgranges B., Eustache F., Beuthien-Baumann B., Menzel C., Schroder J., Kato T., Arahata Y., Henze M., Heiss W.D. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002, 17:302-316.
9. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 1982, 140:566-572.
10. Li X.L., de Wang S., Zhao B.Q., Li Q., Qu H.Y., Zhang T., Zhou J.P., Sun M.J. Effects of Chinese herbal medicine fuzhisan on aged rats. Exp. Gerontol. 2008, 43:853-858.
11. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
12. Mielke R., Kessler J., Szelies B., Herholz K., Wienhard K., Heiss W.D. Normal and pathological aging-findings of positron-emission-tomography. J. Neural Transm. 1998, 105:821-837.
13. Potkin S.G., Anand R., Fleming K., Alva G., Keator D., Carreon D., Messina J., Wu J.C., Hartman R., Fallon J.H. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int. J. Neuropsychopharmacol. 2001, 4:223-230.
14. Rapoport S.I., Hatanpaa K., Brady D.R., Chandrasekaran K. Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease. Neurodegeneration 1996, 5:473-476.
15. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 1984, 141:1356-1364.
16. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 1994, 53:438-447.
17. Shi-rong W., De-sheng W., Jing-·yan Z., Shu-li S. Effect of fuzhisan on the area of neurosome and the length of axon. Chin. J. Clin. Rehabil. 2005, 9:241-243.
18. Sultzer D.L., Mahler M.E., Mandelkern M.A., Cummings J.L., Van Gorp W.G., Hinkin C.H., Berisford M.A. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 1995, 7:476-484.
19. Talairach J., Tornoux P. Co-planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging 1988, Georg Thieme, Stuttgart.
20. Talbot P.R., Lloyd J.J., Snowden J.S., Neary D., Testa H.J. Choice of reference region in the quantification of single-photon emission tomography in primary degenerative dementia. Eur. J. Nucl. Med. 1994, 21:503-508.
21. Teipel S.J., Drzezga A., Bartenstein P., Moller H.J., Schwaiger M., Hampel H. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology (Berl) 2006, 187:86-94.
22. Yang H., Wen S.R., Zhang G.W., Wang T.G., Hu F.X., Li X.L., Wang D.S. Effects of Chinese herbal medicine fuzhisan on autologous neural stem cells in the brain of SAMP-8 mice. Exp. Gerontol. 2011.
23. Zhang Z., Zhao R., Tang Y., Wen S., Wang D., Qi J. Fuzhisan, a Chinese herbal medicine, inhibits beta-amyloid-induced neurotoxicity and Tau phosphorylation through calpain/Cdk5 pathway in cultured cortical neurons. Neurochem. Res. 2011, 36:801-811.
24. Zhao J., Wang D., Duan S., Wang J., Bai J., Li W. Analysis of fuzhisan and quantitation of baicalin and ginsenoside Rb(1) by HPLC-DAD-ELSD. Arch. Pharm. Res. 2009, 32:989-996.